Article 1 to 10 out of 27 concerning OctoPlus N.V.
OctoPlus announces further efficiency measures(25 Sep 2009) OctoPlus N.V. announced that it will reduce its work force by approximately 25% while retaining its revenue guidance for the year. Reductions will occur across all areas of the Company and have taken place in consultation with the Company's Works ...
OctoPlus signs service contract with Axentis Pharma(14 Sep 2009) OctoPlus N.V. announced that it has signed a pharmaceutical development and manufacturing contract with a new client, Axentis Pharma AG. The undisclosed contract value contributes to OctoPlus' annual revenues, for which the Company reiterates its ...
OctoPlus wins expansion of drug delivery evaluation contract with existing client(08 Sep 2009) OctoPlus N.V. announced that it has won an expansion of a drug delivery technology evaluation contract with an existing client, a global pharmaceutical company. In 2008 and 2009 OctoPlus performed preliminary feasibility work for this client and ...
OctoPlus announces change in Executive Board(27 Aug 2009) OctoPlus N.V. announced that Joost Holthuis has decided to step down as Chief Scientific Officer after successfully leading the Company for almost 15 years since he founded OctoPlus in 1995. The Company will continue to have access to Mr. Holthuis' ...
OctoPlus wins new service contract(12 Aug 2009) OctoPlus N.V. announced that it has signed a pharmaceutical development and manufacturing contract with a new client, a European mid-sized pharmaceutical company. The undisclosed contract value significantly contributes to OctoPlus' annual ...
OctoPlus appoints Susan Swarte as Chief Financial Officer(30 Jun 2009) OctoPlus N.V. announced that Susan Swarte will join the Company on 1 August as Chief Financial Officer. At the next general meeting of shareholders the Board of Supervisory Directors will propose to appoint Mrs. Swarte as member of the Executive ...
OctoPlus opens new GMP manufacturing facility(24 Jun 2009) OctoPlus N.V. announced that it has started pharmaceutical production in its new manufacturing facility in Leiden. The facility has received a license from the Dutch authorities to manufacture pharmaceutical products according to international GMP ...
OctoPlus wins new drug delivery evaluation contract for two compounds(08 Jun 2009) As part of the Company's strategic focus on developing controlled release formulations for clients, OctoPlus N.V. announced that it has signed a new drug delivery technology evaluation contract for two compounds with a European biotech company. ...
OctoPlus' licensee Biolex commences Phase IIb study with Locteron(22 Apr 2009) OctoPlus N.V. announced that its licensee Biolex Therapeutics has commenced patient dosing in the SELECT-2 Phase IIb clinical study of Locteron®, a controlled release formulation of interferon alpha for the treatment of chronic hepatitis C. ...
OctoPlus wins new drug delivery evaluation contract(08 Apr 2009) As part of the Company's strategic focus on developing controlled release formulations for clients, OctoPlus N.V. announced that it has signed a new drug delivery technology evaluation contract with a European biotech company. This is the seventh ...
Top
